The Disciplinary Committee of the Royal College of Veterinary Surgeons has suspended a veterinary surgeon for a period of three months for practising veterinary surgery while not registered with the College.

At a hearing which concluded on 9 September, Silke Birgitt Lindridge, of the Consett Veterinary Centre, Medomsley Road, Consett, County Durham, was found guilty of disgraceful conduct in a professional respect for practising when she ought to have known that her name had been removed from the RCVS Register for non-payment of fees.

The Committee heard that Mrs Lindridge, who qualified as a veterinary surgeon at the University of Berlin in 1997, had returned to Germany whilst on maternity leave in September 2006 but had continued to be the sole principal of two practices, the Consett Veterinary Centre, and the Winlaton Veterinary Centre in Tyne and Wear. She had continued to run the practices whilst in Germany, and had returned to the UK on several occasions during 2007, when she practised veterinary surgery on small animals and horses. She had not been registered with the College for the period between 5 June 2006 and 2 April 2008.

To practise veterinary surgery when unregistered is a criminal offence. However, after consultation with the Crown Prosecution Service, a decision was taken that it was not in the public interest to prosecute Mrs Lindridge and that the matter should be left with the RCVS Disciplinary Committee.

Mrs Lindridge claimed not to be aware that she was unregistered, stating that a fee notice and reminder, as well as a telephone call and correspondence from the College about her registration status, had not been brought to her attention by her practice administrators. The Committee accepted that she had not known, but decided that, as registration was a professional obligation, Mrs Lindridge should have known that her name had been removed from the Register, a charge that Mrs Lindridge accepted. The Committee felt that: "The failure of Mrs Lindridge to put in place proper systems for the administration of her practice, including the payment of her annual retention fee... was lamentable." The way in which the practice had paid its bills during her absence demonstrated an "utterly careless attitude to the administration of the practice".

Taking account of the fact that Mrs Lindridge had not knowingly practised while unregistered, and the positive support of her clients, the Committee decided that a three-month period of suspension from the Register was appropriate.

Beverley Cottrell, chairing the Committee, commented: "The Committee would like to make it clear that it is the personal responsibility of every practising veterinary surgeon to ensure that the annual retention fee is paid and that their names are on the Register. It is in the public interest that clients should be assured that the practitioner is a regulated person, who is capable of providing valid certificates."

She continued: "The record of Mrs Lindridge's practice during 2007 discloses that she was providing certificates for horses and small animals whilst she was unregistered. Those certificates are invalid. She was also prescribing prescription-only drugs when she was not entitled to do so. The Committee considers that a short period of suspension is proportionate to the nature and the extent of the charge, the public interest and the interests of Mrs Lindridge."

Norbrook Laboratories has launched Closamectin, a parasiticide which the company says will revolutionise cattle farming and parasite control in meat producing animals.

Closamectin Pour-on is a solution which can quite literally be poured onto the back of animals. It simultaneously treats fluke, worms and external parasites. The new product is the culmination of a six year research project costing £3.5 million and involving 80 scientists at the company's headquarters in Newry Co Down.

Norbrook says it will bring immense benefits for farmers whose cattle are often ravaged by parasitic attack. Fluke in particular can have devastating effects both on beef and dairy herds, seriously weakening, and in some cases killing the animals by destroying their livers. At the very least it collectively costs farmers around £17 million per annum by reducing the weight of beef cattle and the milk yields of dairy cows.

Fluke used to be confined to the western parts of Britain, together with Scotland and Ireland, but global warming has seen other parts of the UK experiencing the same mild and wet conditions on which the parasite thrives. Consequently it is on the rise.

Currently fluke is treated by injection or oral drench - both time-consuming and difficult processes for the farmers which can also be stressful for the animals. In contrast pour-on solutions can be applied swiftly and easily with no detrimental impact on cattle.

Norbrook has been awarded licenses for Closamectin Pour-on in both the UK and Ireland. This is a very significant market: the countries have a combined cattle population of 17 million. There are also plans to roll out the product in other countries.

Developing a pour-on to deal with these parasites has baffled scientists for 20 years. Alistair Couper, Norbrook's Chief Vet said: "This is the Holy Grail of farm animal veterinary medicine. It was a highly complex challenge for our research team. They had to develop a product which would treat different conditions simultaneously and have a molecular structure which could be absorbed straight through the skin. This is a ground breaking achievement and a brilliant piece of science"

Lord Ballyedmond, Chairman of Norbrook Laboratories said: "This is a very important milestone for Norbrook and for livestock and farmers worldwide. We have invested heavily in research and development and the results are there for all to see. We are delighted to have beaten other multinationals.  We have now developed the world's most effective remedy for parasite control in cattle that our entering the food chain. I am pleased to state that our business has grown this year indigenously at 12% despite the recession, beating our competitors. This tremendous breakthrough is a great testimony to the brilliance of our scientists in Newry and also to our policy of investing in research. "